✦ LIBER ✦

The treatment of advanced hodgkin's disease

✍ Scribed by Straus, D. J. ;Lee, B. J. ;Koziner, B. ;Nisce, L. Z. ;Young, C. W. ;Clarkson, B. D.

Publisher: Springer-Verlag
Year: 1981
Weight: 353 KB
Volume: 43
Category: Article
ISSN: 1432-0584
DOI: 10.1007/bf00320472

No coin nor oath required. For personal study only.

✦ Synopsis

Between January, 1975, and December, 1978, 118 patients with advanced Hodgkin's disease were treated with 8 months of alternating MOPP and adriamycin, bleomycin, dacarbazine and vinblastine (ABDV) combined with 1 month of low-dose radiation therapy (2,000 rad) to areas initially involved with bulky disease. Among 57 evaluable previously-untreated patients, 50/57 (88%) achieved complete and 7/57 (12%) partial remissions. The estimated relapse rate among the complete responders was 16% at 36 months from date of remission. Toxicity was comparable to that of other combination chemotherapy regimens. These results are among the best reported for the treatment of patients with advanced Hodgkin's disease.

📜 SIMILAR VOLUMES

Vinblastine in the treatment of advanced

Vinblastine in the treatment of advanced Hodgkin's disease

✍ Dr. W. Davies Sohier Jr.; Rose K. L. Wong; Alan C. Aisenberg 📂 Article 📅 1968 🏛 John Wiley and Sons 🌐 English ⚖ 470 KB 👁 3 views

In 35 cases of advanced Hodgkin's disease (stage IIIB to IVB), of whom 33 were no longer responsive to the alkylating agents, vinblastine produced clinically useful remissions in 22 patients or 64%. Complete objective responses were unusual but one third of these cases experienced partial remissions

Alternating chemotherapy and irradiation

Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease

✍ Richard T. Hoppe; Carol S. Portlock; Eli Glatstein; Saul A. Rosenberg; Henry S. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 794 KB

Improved survival in the treatment of ad

Improved survival in the treatment of advanced hodgkin's disease at a nonuniversity institution (1970–1979)

✍ William R. Friedenberg; P. Dirks; E. Beltaos; J. J. Mazza; J. L. Hoehn; R. H. Gr 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB 👁 2 views

From 1970 through 1979, 89 patients with Hodgkin's disease were treated at the Marshfield Clinic/St. Joseph's Hospital. After the pathologic material was reviewed, the patients were analyzed to compare Group I (1970-1973) with Group I1 (1974)(1975)(1976)(1977)(1978)(1979). Demographic characteristic

The superiority of CCNU in the treatment

The superiority of CCNU in the treatment of advanced hodgkin's disease: Cancer and leukemia group b study

✍ Heine H. Hansen; Oleg S. Selawry; Thomas F. Pajak; Charles L. Spurr; Geoffrey Fa 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

A new effective four-drug combination of

A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease

✍ M. Robert Cooper; Thomas F. Pajak; Nis I. Nissen; Leon Stutzman; Kurt Brunner; J 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 833 KB

Acute myelogenous leukemia as a second m

Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease

✍ Alfred A. Bartolucci; Charlene Liu; John R. Durant; Richard A. Gams 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB 👁 2 views